Applicants: Hector F. DeLuca et al Attorney Docket 1256-00941

Listing of Claims:

Please cancel claims 1-16 and 22-77.

1-16. (Canceled)

17. (Original) A method of treating an inflammatory disease selected from the group consisting of rheumatoid arthritis, asthma, and inflammatory bowel diseases, comprising administering to a patient with said disease an effective amount of (20S)- 1α -hydroxy- 2α -methyl-19-nor-vitamin D₃ having the formula:

- 18. (Original) The method of claim 17 wherein (20S)- 1α -hydroxy- 2α -methyl-19-nor-vitamin D₃ is administered orally.
- 19. (Original) The method of claim 17 wherein (20S)- 1α -hydroxy- 2α -methyl-19-nor-vitamin D₃ is administered parenterally.
- 20. (Original) The method of claim 17 wherein (20S)- 1α -hydroxy- 2α -methyl-19-nor-vitamin D₃ is administered transdermally.
- 21. (Original) The method of claim 17 wherein (20S)- 1α -hydroxy- 2α -methyl-19-nor-vitamin D₃ is administered in a dosage of from about $0.01\mu g/day$ to about $100 \mu g/day$.

22-77. (Canceled)